158 related articles for article (PubMed ID: 30598020)
1. Direct Hospitalization Cost of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Vietnam.
Ngo CQ; Thi Bui T; Vu GV; Chu HT; Phan PT; Ngoc Pham H; Vu GT; Nguyen LH; Ha GH; Tran BX; Latkin CA; Ho CSH; Ho RCM
Int J Environ Res Public Health; 2018 Dec; 16(1):. PubMed ID: 30598020
[TBL] [Abstract][Full Text] [Related]
2. Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease.
Ornek T; Tor M; Altın R; Atalay F; Geredeli E; Soylu O; Erboy F
Int J Med Sci; 2012; 9(4):285-90. PubMed ID: 22701335
[TBL] [Abstract][Full Text] [Related]
3. [Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].
Jahnz-Różyk K; Targowski T; From S; Faluta T; Borowiec L
Pneumonol Alergol Pol; 2011; 79(5):337-42. PubMed ID: 21861257
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland].
Jahnz-Rózyk K; Targowski T; From S
Pneumonol Alergol Pol; 2008; 76(6):426-31. PubMed ID: 19173191
[TBL] [Abstract][Full Text] [Related]
5. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
6. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.
Toy EL; Gallagher KF; Stanley EL; Swensen AR; Duh MS
COPD; 2010 Jun; 7(3):214-28. PubMed ID: 20486821
[TBL] [Abstract][Full Text] [Related]
7. Clinical factors and comorbidities affecting the cost of hospital-treated COPD.
Deniz S; Şengül A; Aydemir Y; Çeldir Emre J; Özhan MH
Int J Chron Obstruct Pulmon Dis; 2016; 11():3023-3030. PubMed ID: 27980399
[TBL] [Abstract][Full Text] [Related]
8. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality.
Perera PN; Armstrong EP; Sherrill DL; Skrepnek GH
COPD; 2012 Apr; 9(2):131-41. PubMed ID: 22409371
[TBL] [Abstract][Full Text] [Related]
9. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
Jahnz-Rózyk K; Targowski T; From S
Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
[TBL] [Abstract][Full Text] [Related]
10. Economic outcomes among chronic obstructive pulmonary disease Vietnamese patients: Approach considerations from a social perspective.
Vu TQ; Vo TQ
J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S64-S74. PubMed ID: 31369536
[TBL] [Abstract][Full Text] [Related]
11. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Moll K; Sun SX; Ellis JJ; Howe A; Amin A
Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
[TBL] [Abstract][Full Text] [Related]
12. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
13. Factors contributing to hospitalization costs for patients with COPD in China: a retrospective analysis of medical record data.
Li M; Wang F; Chen R; Liang Z; Zhou Y; Yang Y; Chen S; Ung COL; Hu H
Int J Chron Obstruct Pulmon Dis; 2018; 13():3349-3357. PubMed ID: 30349238
[TBL] [Abstract][Full Text] [Related]
14. Economic analysis in admitted patients with acute exacerbation of chronic obstructive pulmonary disease.
Chen YH; Yao WZ; Cai BQ; Wang H; Deng XM; Gao HL; Huang JS; Wang XM
Chin Med J (Engl); 2008 Apr; 121(7):587-91. PubMed ID: 18466676
[TBL] [Abstract][Full Text] [Related]
15. [Costs of the last hospitalization for patients with acute exacerbation of chronic obstructive pulmonary disease and patients with lung cancer].
Zhu ML; Cai BQ
Zhonghua Jie He He Hu Xi Za Zhi; 2009 Apr; 32(4):258-61. PubMed ID: 19576037
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of medical expenditure with nebulized budesonide versus systemic corticosteroids in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease in China.
Zhang J; Yao W; You X; Liu T; Liu Y
Int J Chron Obstruct Pulmon Dis; 2019; 14():1195-1207. PubMed ID: 31213797
[No Abstract] [Full Text] [Related]
17. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).
Friedman M; Menjoge SS; Anton SF; Kesten S
Pharmacoeconomics; 2004; 22(11):741-9. PubMed ID: 15250751
[TBL] [Abstract][Full Text] [Related]
18. [Retrospective analysis of direct costs of hospital treatment of chronic obstructive pulmonary disease exacerbations].
Jahnz-Rózyk K; Targowski T; From S; Płusa T
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():91-4. PubMed ID: 15524028
[TBL] [Abstract][Full Text] [Related]
19. Hospitalization Due to Co-Morbid Conditions is the Main Cost Driver Among Subjects With COPD-A Report From the Population-Based OLIN COPD Study.
Jansson SA; Backman H; Rönmark E; Lundbäck B; Lindberg A
COPD; 2015 Aug; 12(4):381-9. PubMed ID: 25415366
[TBL] [Abstract][Full Text] [Related]
20. Factors contributing to high-cost hospital care for patients with COPD.
Mulpuru S; McKay J; Ronksley PE; Thavorn K; Kobewka DM; Forster AJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():989-995. PubMed ID: 28392683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
